A Phase II Trial of Imatinib Mesylate in Merkel Cell Carcinoma (Neuroendocrine Carcinoma of the Skin): A Southwest Oncology Group Study (S0331)

BACKGROUND: Imatinib mesylate (Gleevec(®)) was evaluated as a treatment for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) based on the identification of strong c-KIT staining of these neoplasms. METHODS: Eligibility included patients with measurable metastatic or unresectable MCC...

Full description

Saved in:
Bibliographic Details
Main Authors: Samlowski, Wolfram E., Moon, James, Tuthill, Ralph J., Heinrich, Michael C., Balzer-Haas, Naomi S., Merl, Stuart A., DeConti, Ronald C., Thompson, John A, Witter, Merle T., Flaherty, Lawrence E., Sondak, Vernon K.
Format: Artigo
Language:Inglês
Published: 2010
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2978644/
https://ncbi.nlm.nih.gov/pubmed/20019577
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/COC.0b013e3181b9cf04
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items